The agency has ordered compounding pharmacies to stop making compound versions of GLP-1 drugs now that the drugs are no longer in short supply. Eli Lilly, the maker of Zepbound and Mounjaro, and Novo ...

The FDA says state-licensed compounding pharmacies must immediately stop making compound versions of GLP-1 drugs. Larger, national licensed facilities making compound versions of Zepbound have until ...

Guttman-Yassky received research support, consulting, or lecture fees on atopic dermatitis from Regeneron, Sanofi, Pfizer, ...

The Chronic Pruritus Market is making significant strides, fueled by innovative treatment approaches and ongoing research ...

The FDA has approved Stoboclo (denosumab-bmwo), a biosimilar to Prolia (denosumab), and Osenvelt (denosumab-bmwo), a biosimilar to Xgeva (denosumab).

Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...

Insights shed light on what the approval means for providers and their patients affected by this neurodegenerative retinal ...

In the ECHELON-3 study, the brentuximab vedotin combination with lenalidomide and rituximab reduced mortality risk by 37% compared with placebo.

With a U.S. green light for its encapsulated cell therapy technology in the bag, privately held biotech Neurotech ...

The ruxolitinib cream met its primary end point as a treatment for prurigo nodularis in one phase 3 trial but fell short in ...

Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its financial results for the full year ...